Keith Flaherty Explained

Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School.[1] He was previously a professor of medicine at the University of Pennsylvania. He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib.[2] [3] [4] [5] In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs.[6]

Notes and References

  1. http://www.massgeneral.org/cancer/doctors/doctor.aspx?ID=18371 Keith T. Flaherty, MD - Massachusetts General Hospital, Boston, MA
  2. https://www.nytimes.com/2010/02/22/health/research/22trial.html?em Target Cancer - A Roller Coaster Chase for a Cure - Series - NYTimes.com
  3. https://www.nytimes.com/2010/02/23/health/research/23trial.html?hp Target Cancer - After Long Fight, Melanoma Drug Gives Sudden Reprieve - Series - NYTimes.com
  4. https://www.nytimes.com/2010/02/24/health/research/24trial.html?hpw Target Cancer - A Drug Trial Cycle - Recovery, Relapse, Reinvention - Series - NYTimes.com
  5. http://www.nejm.org/doi/full/10.1056/NEJMoa1002011 Inhibition of Mutated, Activated BRAF in Metastatic Melanoma — NEJM
  6. Web site: MGH, AstraZeneca partner to create new drug combos . Boston Globe . 19 May 2013 . 30 January 2015 . Weintraub, Karen.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Keith Flaherty".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.